Vaxart Statistics
Total Valuation
Vaxart has a market cap or net worth of $144.12 million. The enterprise value is $126.95 million.
| Market Cap | 144.12M |
| Enterprise Value | 126.95M |
Important Dates
The last earnings date was Monday, May 13, 2024, after market close.
| Earnings Date | May 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaxart has 176.84 million shares outstanding. The number of shares has increased by 24.85% in one year.
| Shares Outstanding | 176.84M |
| Shares Change (YoY) | +24.85% |
| Shares Change (QoQ) | +19.01% |
| Owned by Insiders (%) | 1.13% |
| Owned by Institutions (%) | 22.96% |
| Float | 159.93M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 45.87 |
| PS Ratio | 16.22 |
| Forward PS | 10.14 |
| PB Ratio | 2.59 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 14.29 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.14, with a Debt / Equity ratio of 0.35.
| Current Ratio | 3.14 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -121.10% and return on invested capital (ROIC) is -108.87%.
| Return on Equity (ROE) | -121.10% |
| Return on Assets (ROA) | -80.00% |
| Return on Capital (ROIC) | -108.87% |
| Revenue Per Employee | $81,514 |
| Profits Per Employee | -$749,927 |
| Employee Count | 109 |
| Asset Turnover | 0.09 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Vaxart has paid $277,000 in taxes.
| Income Tax | 277,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -33.20% in the last 52 weeks. The beta is 0.72, so Vaxart's price volatility has been lower than the market average.
| Beta (1Y) | 0.72 |
| 52-Week Price Change | -33.20% |
| 50-Day Moving Average | 0.92 |
| 200-Day Moving Average | 0.85 |
| Relative Strength Index (RSI) | 45.84 |
| Average Volume (30 Days) | 1,559,766 |
Short Selling Information
The latest short interest is 18.60 million, so 10.52% of the outstanding shares have been sold short.
| Short Interest | 18.60M |
| Short Previous Month | 18.47M |
| Short % of Shares Out | 10.52% |
| Short % of Float | 11.63% |
| Short Ratio (days to cover) | 12.72 |
Income Statement
In the last 12 months, Vaxart had revenue of $8.89 million and -$81.74 million in losses. Loss per share was -$0.53.
| Revenue | 8.89M |
| Gross Profit | 8.89M |
| Operating Income | -81.85M |
| Pretax Income | -81.47M |
| Net Income | -81.74M |
| EBITDA | -72.73M |
| EBIT | -81.47M |
| Loss Per Share | -$0.53 |
Balance Sheet
The company has $36.66 million in cash and $19.49 million in debt, giving a net cash position of $17.17 million or $0.10 per share.
| Cash & Cash Equivalents | 36.66M |
| Total Debt | 19.49M |
| Net Cash | 17.17M |
| Net Cash Per Share | $0.10 |
| Equity / Book Value | 55.69M |
| Book Value Per Share | 0.31 |
| Working Capital | 30.17M |
Cash Flow
In the last 12 months, operating cash flow was -$67.18 million and capital expenditures -$643,000, giving a free cash flow of -$67.83 million.
| Operating Cash Flow | -67.18M |
| Capital Expenditures | -643,000 |
| Free Cash Flow | -67.83M |
| FCF Per Share | -$0.40 |
Margins
Gross margin is 100.00%, with operating and profit margins of -921.16% and -920.00%.
| Gross Margin | 100.00% |
| Operating Margin | -921.16% |
| Pretax Margin | -916.88% |
| Profit Margin | -920.00% |
| EBITDA Margin | -818.53% |
| EBIT Margin | -916.88% |
| FCF Margin | -763.39% |
Dividends & Yields
Vaxart does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -24.85% |
| Shareholder Yield | -24.85% |
| Earnings Yield | -56.72% |
| FCF Yield | -47.06% |
Analyst Forecast
The average price target for Vaxart is $3.00, which is 268.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 268.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 93.56% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on February 14, 2018. It was a reverse split with a ratio of 1:11.
| Last Split Date | Feb 14, 2018 |
| Split Type | Reverse |
| Split Ratio | 1:11 |
Scores
Vaxart has an Altman Z-Score of -6.75 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -6.75 |
| Piotroski F-Score | 3 |